Compare Danaos Corporation (DAC) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaos Corporation vs IDEXX Laboratories, Inc. — how do they compare? Danaos Corporation trades at $129.89 (market cap $2.36B), while IDEXX Laboratories, Inc. trades at $534.38 (market cap $42.65B). The key difference: IDEXX Laboratories, Inc. is far larger — about 18.1× Danaos Corporation's market cap, and Danaos Corporation pays a 2.78% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| DAC | IDXX | |
|---|---|---|
Market Cap | $2.36B | $42.65B |
Sector | Technology | Health |
52-Week High | $134.63 | $766.68 |
52-Week Low | $84.05 | $514.61 |
Enterprise Value | $2.36B | $43.56B |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaos Corporation (DAC) trades at $129.35, up 0.75% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 4.57, P/B of 0.6, and net income margin of 49.85% (2026 trend). Recent Q1 2026 earnings beat expectations, and the company maintains a consistent dividend policy. Analyst sentiment is mixed with a 40% buy rating. The stock is near resistance at $130, with RSI_6 indicating potential overbought conditions.
The outlook for DAC remains positive due to attractive valuation, high profitability, and a robust containership backlog. Key risks include exposure to shipping rate volatility and capital allocation decisions. Upside potential is supported by earnings momentum and dividend yield, but investors should monitor industry cyclicality and execution on fleet expansion.
IDXX trades at $564.09, up 0.09% with neutral technical signals. The stock shows strong fundamentals with revenue growth to $4.3B in 2025 and consistent earnings beats. Analyst consensus is bullish (59% Buy) with improving cash flow trends. Recent news highlights AI integration in medical devices and upcoming Q2 2026 earnings.
Outlook remains positive driven by innovation and market leadership in pet healthcare. Risks include high valuation multiples and competitive pressures. Institutional sentiment supports growth, but investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaos Corporation
Danaos is a leading international owner of containerships, providing seaborne transportation services globally. It charters its fleet of vessels to major shipping lines across Asia, Europe, and the Americas.
Read more on DAC →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
